The estimated Net Worth of Eric Francois is at least $651 Thousand dollars as of 21 December 2020. Mr Francois owns over 600 units of Scynexis Inc stock worth over $16,425 and over the last 9 years he sold SCYX stock worth over $0. In addition, he makes $634,250 as Chief Financial Officer at Scynexis Inc.
Mr has made over 3 trades of the Scynexis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 600 units of SCYX stock worth $3,750 on 21 December 2020.
The largest trade he's ever made was buying 15,000 units of Scynexis Inc stock on 24 June 2016 worth over $35,850. On average, Mr trades about 1,793 units every 137 days since 2015. As of 21 December 2020 he still owns at least 11,732 units of Scynexis Inc stock.
You can see the complete history of Mr Francois stock trades at the bottom of the page.
Eric Francois is the Chief Financial Officer at Scynexis Inc.
As the Chief Financial Officer of Scynexis Inc, the total compensation of Mr Francois at Scynexis Inc is $634,250. There are 3 executives at Scynexis Inc getting paid more, with Dr. Marco Taglietti having the highest compensation of $991,270.
Mr Francois is 45, he's been the Chief Financial Officer of Scynexis Inc since . There are 14 older and 1 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
Eric's mailing address filed with the SEC is 1317 CARLTON AVENUE, SUITE 200, , CHARLOTTESVILLE, VA, 22902.
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado, and Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: